FimmCyte Announces Strategic Collaboration with Gedeon Richter in Endometriosis

FimmCyte AG, a pioneering Swiss biotech developing targeted immunotherapies for chronic fibro‑inflammatory diseases, announces a strategic research collaboration and option‑to‑license agreement with Gedeon Richter Plc., a leading pharmaceutical company in women’s health.

FimmCyte was founded to take a differentiated path in women’s health therapeutics: applying immunotherapy precision to complex fibro-inflammatory diseases starting with endometriosis. Endometriosis treatment options remain limited to symptom management and surgery. Endometriosis affects 1 in 10 women globally and can have a profound impact on pain, fertility, and day‑to‑day functioning.

Under the collaboration, FimmCyte and Gedeon Richter will conduct joint research and development activities to accelerate FMC2 path towards the clinic and ultimately to patients. Gedeon Richter will have global exclusive rights if they decide to exercise their exclusive option prior to initiation of the first‑in‑human clinical study.

Dr. Mohaned Shilaih, CEO of FimmCyte, commented: “This collaboration is a major step forward for FimmCyte and the patients we ultimately serve. Gedeon Richter’s leadership in women’s health brings exceptional development capabilities and global reach, and we are excited to combine that strength with FimmCyte’s cutting-edge science. Together, we aim to advance a first‑in‑class, non‑hormonal approach that is designed to go beyond symptom management, and to move as fast as scientific rigor allows toward first‑in‑human evaluation.”

FimmCyte believes FMC2 has the potential to be one of the first disease-modifying treatments for endometriosis, designed to address the root cause of endometriosis. FMC2 is a first-in-class molecule based on FimmCyte’s proprietary antibody platform that is designed to lead to durable clinical management of chronic fibro-inflammatory diseases such as endometriosis. FimmCyte’s pipeline includes multiple additional assets that are engineered for significant unmet medical needs such as organ fibrosis.

Acknowledgments

FimmCyte sincerely thanks the entire FimmCyte team, advisors, and scientific advisory board for their invaluable contribution. We also sincerely thank David Colpman, commercial advisor, and Luzius Zumstein and Christian Wyss of VISCHER, legal counsel.

FimmCyte has been supported by Bio Innovation Institute (BII), UZH (Life Sciences Fund), Innosuisse, BaseLaunch, University Hospital Zurich (USZ), Venture Kick, KickFund, and Gebert Rüf.